PALM BEACH, Florida, October 4, 2018 /PRNewswire/ --
Financialnewsmedia.com News Commentary
If there's one particular segment of the cannabis industry that has gained an enormous amount of attention lately as well as a peaking curiosity by consumers, it most definitely has to be the cannabidiol (CBD) product market. CBD today is now being applied as an active ingredient for a rapidly growing number of popular consumer products. It is used for beauty products because the compound is said to be good for the skin. It is used for pet care products, found in sports creams for its muscle-relaxant features and is quickly becoming very popular for treating anti-anxiety and anti-inflammatory properties which make CBD popular among people suffering from a sleep disorder, epilepsy, depression and chronic pain. According to Hemp Gazette, the remaining part of 2018 as well as next year could by all means be the breakout year based on recent developments in the market including the first US Food and Drug Administration-approved CBD-derived medicine, Epidiolex, is set to rake in $625 Million in sales for a single year once physicians start prescribing it. Looking ahead, New Frontier forecasts the U.S. CBD market will grow to $1.2 billion by 2020, and nearly $2 billion by 2022. Active cannabis companies in the markets this week include Integrated Cannabis Company, Inc. (CSE:ICAN) (OTC:ICNAF), Hexo Corp. (TSX:HEXO) (OTC:HYYDF), Tetra Bio-Pharma Inc. (TSX-V:TBP) (OTC:TBPMF), Cannabix Technologies Inc. (OTC:BLOZF) (CSE:BLO), Trulieve Cannabis Corp. (OTC:TCNNF) (CSE:TRUL).
Integrated Cannabis Company, Inc. (CSE:ICAN) (OTCQB:ICNAF) BREAKING NEWS: Integrated Cannabis Company is pleased to announce the successful completion and positive results of a controlled trial of its proprietary Sleep product. The controlled 60 patient trial was completed with a renowned pain clinic in Southern California and the results were highly favorable; resulting in improvement in patients' sleep patterns combined with the unexpected, but highly desirable, decrease in the level of pain. The study results have been published in the peer reviewed journal: International Journal of Pharmacy and Life Sciences (Int. J. of Pharm. Life Sci., Vol. 9:5722-5729).
"The unique formulation of ingredients in the X-SPRAYS™ sleep supplement contributed to a significant improvement in sleep quality together with a reduction in daytime sleepiness, pain, and depression, when compared to the control group. The study was conducted in a controlled and regulated clinical environment, which prohibits the test of cannabis products. Therefore the study was on our non-cannabinoid product. However, our experience with the infusion of CBD into the tested formulation has rendered profound increased benefits. Furthermore, we are actively seeking clinical study relationships in legal jurisdictions outside of North America for our cannabinoid-based products and expect to replicate the aforementioned study in the near term. The spray has the added benefit of being easy to use, is fast acting, promotes a superb night's rest and does not leave you feeling groggy in the morning", said Dr. Clive Spray, CSO of Integrated Cannabis. Read this and more news for ICAN at http://www.financialnewsmedia.com/news-ican
Other Companies with recent developments or to keep watch for in the cannabis industry include:
Hexo Corp. (TSX:HEXO) (OTCPK:HYYDF) plans to establish a Eurozone processing, production and distribution centre in Greece. The partnership with Greek company Qannabos (QNBS) will catalyze a vertically integrated cannabis enterprise to capitalize on the current medical markets. Hexo's plan to establish operations in Greece marks the company's first foray into the European cannabis market. The move will provide the company presence in Europe to supply a full suite of brands in France, the United Kingdom and other European markets once regulations permit. "I'm excited to add European distribution capabilities for Hexo and its joint venture partners," said Sebastien St-Louis, Hexo's chief executive officer and co-founder. "By bringing brands powered by Hexo, our infrastructure and our know-how to Europe, we will be well prepared to serve a burgeoning market. This new capability will allow us to bring even more value to our hub and spoke partners in the beverage, cosmetics and food space by giving them access to licensed cannabis infrastructure and brands in Europe. Additionally, Hexo believes that we will quickly be able to leverage our joint venture partners' networks to take significant first mover advantage and market share."
Tetra Bio-Pharma Inc. (TSX-V:TBP.V) (OTCQB:TBPMF) a leader in cannabinoid-based drug discovery and development, in partnership with Ford's Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada's first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford's manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford's to conduct the fabrication, packaging and labeling of PPP001.
Cannabix Technologies Inc. (OTCPK:BLOZF) (CSE:BLO) closed up over 3% on Wednesday at $1.63 on the OTC Markets. Cannabix Technologies, a technology company, develops marijuana breathalyzer for law enforcement and the work place in North America. It develops drug-testing devices that will detect tetrahydrocannabinol using breath samples at roadside and identify drivers under the influence of marijuana.
Trulieve Cannabis Corp. (OTCPK:TCNNF) (CSE:TRUL) is a vertically integrated seed-to-sale company and is the first and largest fully licensed medical marijuana company in the state of Florida. Trulieve cultivates and produces all of its products in-house, and distributes those products to Trulieve-branded stores (dispensaries) throughout the state of Florida as well as directly to patients via home delivery. It produces various Trulieve branded products, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges. The company sells its products through 16 Trulieve branded retail locations, as well as directly via home delivery.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty five hundred dollars for news coverage of the current press releases issued by Integrated Cannabis Company, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.